Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
Combined immune checkpoint blockade (ICB) is effective therapy for renal cell carcinoma (RCC). However, the dynamic changes in circulating B cells induced by combined ICB have not been clarified. The present study prospectively examined 22 patients scheduled to receive ICB for unresectable or metastatic RCC between March 2018 and August 2021. Eleven patients received combined therapy with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab), and the other 11 patients received nivolumab monotherapy. Comprehensive phenotypes of circulating immune cells obtained prior to and after ICB therapy were analyzed by flow cytometry. Although the proportion of naïve B cells among total B cells was significantly decreased, that of switched memory B cells was significantly increased after combined therapy. In responders, the proportion of B cells among peripheral blood mononuclear cells was significantly higher prior to ICB therapy, and the proportion of switched memory B cells among total B cells tended to increase after ICB therapy. Of note, the proportion of plasmablasts among total B cells was significantly increased after ICB therapy in patients who developed severe immune-related adverse events (irAEs), and the proportion of B cells among peripheral blood decreased significantly. Furthermore, in four of five patients who developed immune-related hypophysitis following combined therapy, anti-pituitary antibody was detected in the serum. These results suggested that immune-related hypophysitis was closely related to the increase in circulating plasmablasts. Collectively, this study suggests that combined ICB promotes the differentiation of B cell populations, which is associated with efficient tumor suppression and development of irAEs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
Cancer immunology, immunotherapy : CII - 72(2023), 11 vom: 04. Nov., Seite 3543-3558 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Uehara, Koki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
31YO63LBSN |
|---|
| Anmerkungen: |
Date Completed 20.11.2023 Date Revised 26.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00262-023-03505-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360500846 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360500846 | ||
| 003 | DE-627 | ||
| 005 | 20240426233246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00262-023-03505-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM360500846 | ||
| 035 | |a (NLM)37550428 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Uehara, Koki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.11.2023 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a Combined immune checkpoint blockade (ICB) is effective therapy for renal cell carcinoma (RCC). However, the dynamic changes in circulating B cells induced by combined ICB have not been clarified. The present study prospectively examined 22 patients scheduled to receive ICB for unresectable or metastatic RCC between March 2018 and August 2021. Eleven patients received combined therapy with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab), and the other 11 patients received nivolumab monotherapy. Comprehensive phenotypes of circulating immune cells obtained prior to and after ICB therapy were analyzed by flow cytometry. Although the proportion of naïve B cells among total B cells was significantly decreased, that of switched memory B cells was significantly increased after combined therapy. In responders, the proportion of B cells among peripheral blood mononuclear cells was significantly higher prior to ICB therapy, and the proportion of switched memory B cells among total B cells tended to increase after ICB therapy. Of note, the proportion of plasmablasts among total B cells was significantly increased after ICB therapy in patients who developed severe immune-related adverse events (irAEs), and the proportion of B cells among peripheral blood decreased significantly. Furthermore, in four of five patients who developed immune-related hypophysitis following combined therapy, anti-pituitary antibody was detected in the serum. These results suggested that immune-related hypophysitis was closely related to the increase in circulating plasmablasts. Collectively, this study suggests that combined ICB promotes the differentiation of B cell populations, which is associated with efficient tumor suppression and development of irAEs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-CTLA-4 antibody | |
| 650 | 4 | |a Anti-PD-1 antibody | |
| 650 | 4 | |a B cell differentiation | |
| 650 | 4 | |a Hypophysitis | |
| 650 | 4 | |a Renal cell carcinoma | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Tanoue, Kenro |e verfasserin |4 aut | |
| 700 | 1 | |a Yamaguchi, Kyoko |e verfasserin |4 aut | |
| 700 | 1 | |a Ohmura, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Mamoru |e verfasserin |4 aut | |
| 700 | 1 | |a Matsushita, Yuzo |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuchihashi, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Tamura, Shingo |e verfasserin |4 aut | |
| 700 | 1 | |a Shimokawa, Hozumi |e verfasserin |4 aut | |
| 700 | 1 | |a Isobe, Taichi |e verfasserin |4 aut | |
| 700 | 1 | |a Shibata, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ariyama, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Risa |e verfasserin |4 aut | |
| 700 | 1 | |a Kusaba, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Hidetaka |e verfasserin |4 aut | |
| 700 | 1 | |a Oda, Yoshinao |e verfasserin |4 aut | |
| 700 | 1 | |a Akashi, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Baba, Eishi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer immunology, immunotherapy : CII |d 1982 |g 72(2023), 11 vom: 04. Nov., Seite 3543-3558 |w (DE-627)NLM012922226 |x 1432-0851 |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2023 |g number:11 |g day:04 |g month:11 |g pages:3543-3558 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00262-023-03505-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2023 |e 11 |b 04 |c 11 |h 3543-3558 | ||